These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 25518352

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK, Kyprianou N.
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [Abstract] [Full Text] [Related]

  • 4. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ, Milowsky MI, Whang YE.
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C, Yeh S, Niu Y, Li G, Zheng J, Li L, Chang C.
    Cancer Lett; 2017 Jul 01; 397():133-143. PubMed ID: 28323036
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
    Sung YY, Cheung E.
    Endocr Relat Cancer; 2014 Feb 01; 21(1):R1-R11. PubMed ID: 24152433
    [Abstract] [Full Text] [Related]

  • 10. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
    Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP.
    Oncogene; 2014 May 29; 33(22):2815-25. PubMed ID: 23752196
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V, Menon M, Thamilselvan S.
    Int J Cancer; 2016 Oct 01; 139(7):1632-47. PubMed ID: 27198552
    [Abstract] [Full Text] [Related]

  • 14. Androgen receptor antagonists in castration-resistant prostate cancer.
    Rathkopf D, Scher HI.
    Cancer J; 2013 Oct 01; 19(1):43-9. PubMed ID: 23337756
    [Abstract] [Full Text] [Related]

  • 15. [The concept and mechanisms of castration-resistant prostate cancer].
    Naito S, Shiota M.
    Nihon Rinsho; 2014 Dec 01; 72(12):2090-4. PubMed ID: 25518339
    [Abstract] [Full Text] [Related]

  • 16. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
    Mitani T, Harada N, Tanimori S, Nakano Y, Inui H, Yamaji R.
    J Nutr Sci Vitaminol (Tokyo); 2014 Dec 01; 60(4):276-82. PubMed ID: 25297617
    [Abstract] [Full Text] [Related]

  • 17. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
    Rajaram P, Rivera A, Muthima K, Olveda N, Muchalski H, Chen QH.
    Molecules; 2020 May 24; 25(10):. PubMed ID: 32456317
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
    Sharp A, Welti J, Blagg J, de Bono JS.
    Clin Cancer Res; 2016 Sep 01; 22(17):4280-2. PubMed ID: 27330057
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.